TROP2 expression as prognostic marker for gastric carcinoma.
Standard
TROP2 expression as prognostic marker for gastric carcinoma. / Mühlmann, G; Spizzo, G; Gostner, J; Zitt, M; Maier, Hannes; Moser, P; Gastl, G; Müller, H M; Margreiter, R; Ofner, D; Fong, D.
In: J CLIN PATHOL, Vol. 62, No. 2, 2, 2009, p. 152-158.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - TROP2 expression as prognostic marker for gastric carcinoma.
AU - Mühlmann, G
AU - Spizzo, G
AU - Gostner, J
AU - Zitt, M
AU - Maier, Hannes
AU - Moser, P
AU - Gastl, G
AU - Müller, H M
AU - Margreiter, R
AU - Ofner, D
AU - Fong, D
PY - 2009
Y1 - 2009
N2 - BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies. Expression of TROP2 has been shown to be associated with tumour aggressiveness and poor prognosis in patients with various epithelial cancers. AIMS: To investigate TROP2 expression in gastric cancer and its correlation with clinicopathological features and disease outcome. METHODS: Expression of TROP2 was investigated by immunohistochemistry of tumour specimens from 104 patients who underwent resection for gastric cancer. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. RESULTS: TROP2 was found to be overexpressed in 58 (56%) tumour samples. Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03). In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03). Among the total group, TROP2 overexpression was predictive for poor disease-free (p
AB - BACKGROUND: In gastric cancer the recurrence rate is unacceptably high, even after R0 resection and (neo)adjuvant chemotherapy. Therefore, there is an urgent need for identification of predictive and/or prognostic biomarkers to select high-risk patients who might benefit from additional therapies. Expression of TROP2 has been shown to be associated with tumour aggressiveness and poor prognosis in patients with various epithelial cancers. AIMS: To investigate TROP2 expression in gastric cancer and its correlation with clinicopathological features and disease outcome. METHODS: Expression of TROP2 was investigated by immunohistochemistry of tumour specimens from 104 patients who underwent resection for gastric cancer. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. RESULTS: TROP2 was found to be overexpressed in 58 (56%) tumour samples. Significantly higher expression of TROP2 could be detected in intestinal-type carcinomas (p = 0.03). In intestinal-type gastric cancer, TROP2 overexpression was significantly correlated with shorter disease-free survival (DFS) (p = 0.03). Among the total group, TROP2 overexpression was predictive for poor disease-free (p
M3 - SCORING: Zeitschriftenaufsatz
VL - 62
SP - 152
EP - 158
JO - J CLIN PATHOL
JF - J CLIN PATHOL
SN - 0021-9746
IS - 2
M1 - 2
ER -